Business Wire

Toshiba Tec Showcases Digital Signage Solutions at NRF 2018 Retail's Big Show

Del

Toshiba Tec Printing Solutions Business Group (TOKYO: 6588) today announced it will feature its digital signage solutions at the world’s largest retail tradeshow, the NRF (National Retail Federation) 2018 Retail’s Big Show taking place Jan. 14-16 at the Jacob K. Javits Convention Center in New York.

Based on its theme, “The Joy of Shopping,” Toshiba Tec will demonstrate its latest suite of products and solutions at booth 2553, including the company’s innovative digital signage solutions tailored to retail customers.

Retailers acknowledge that digital signage is a vital technology for bolstering sales. As the global market share leader in point-of-sale (POS) systems, Toshiba Tec is well-positioned to deliver state-of-the-art digital signage solutions to worldwide customers via its group company, Toshiba Global Commerce Solutions. Toshiba’s digital signage is currently in use within diverse retail environments including apparel, specialty and grocery stores.

- XSellRate: XSellRate integrates an array of premium features for a more engaging and enriching shopping experience. The multifunction kiosk enables shoppers to quickly and easily place deli orders, find in-store items and receive meal preparation ideas.
- Up Sell: The interactive Up Sell application displays important product information whenever an item is lifted from its in-store shelf. This technology better allows customers to engage with a retailer’s products without the need for additional sales staff.
- Cross Sell: The Cross Sell mobile application is designed to provide sales associates with the information needed to influence shopping behavior. Through the use of a mobile POS system and digital content, sales associates may quickly and easily check inventory based on an item’s size and color while making recommendations based on other items of interest.

Beyond digital signage solutions, Toshiba Tec Printing Solutions Business Group also develops the following products and solutions to streamline document management and workflow needs for retailers: multifunction printers and customizable user interface, mobile point-of-purchase printing and form & label solutions, barcode printers, and managed print services.

For more information about Digital Signage in United States, please visit: http://business.toshiba.com/usa/digital-signage/digital-signage.html

About Toshiba Tec

Toshiba Tec Corporation is a Toshiba’s group company, a leading provider of technology solutions, operating across multiple industries – ranging from retail, education and business services to hospitality and manufacturing. With headquarters in Japan and over 80 subsidiaries worldwide, Toshiba Tec Corporation helps organizations transform the way they create, record, share, manage and display information.

Please visit http://www.toshibatec.co.jp/en/
For Global site please visit http://www.toshibatec.com/global/

Unless otherwise specified and/or credited all images, artwork, text and graphics, logos and logotypes are the copyright and/or trademark of the respective owners. All rights reserved.

Contact information

Media Contact
Toshiba Tec Corporation
Toshihiko “Tommy” Minato, +81-(0)50-3681-5528
Marketing Department
Products, Marketing & Service Division
Printing Solutions Business Group
Toshihiko_Minato@toshibatec.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00Pressemelding

Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/

Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53Pressemelding

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm

Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00Pressemelding

Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian

PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07Pressemelding

PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b

Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17Pressemelding

Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr

Asuragen to Present at World CB & CDx Europe Summit in London, UK24.4.2018 12:00Pressemelding

Asuragen, Inc., a molecular diagnostics company delivering easy to use products for complex testing in genetics and oncology, announced that its senior vice president of commercial operations, Colin Hill, will chair a roundtable discussion during the 2018 World Clinical Biomarkers & Companion Diagnostic (CB & CDx) Europe Summit taking place May 1-3 in London, UK. The session will focus on the imminent changes to the regulatory environment in Europe and the implications for pharmaceutical and diagnostic companies collaborating to advance precision medicine. “Precision medicine is becoming a reality around the world, and the regulations that guide it are rapidly evolving,” said Hill. “It is essential that we build close collaboration between the pharmaceutical, medical device and in vitro diagnostics industry if we are going to successfully navigate this new environment. While our success will definitely leverage learnings from the US experience, we will have to broaden our thinking as w